A human study by Alvarez et al. [57] evaluated the effects of Cerebrolysin, DON, and combined therapy on BDNF serum levels and cognition at week 16 and week 28 after treatment of mild-to-moderate AD patients. This evidence concerns the gene BDNF and Alzheimer disease.